RE:RE:RE:Here are some recent ProMetic Life Sciences analyst reportsOld Dave Martin continues to sow seeds of doubt. Regarding Pg deficiency, at least this time he has acknowledged PLI's estimates of 2100 patients that require operations to remove lesions. It will be up to PLI's marketing team to determine the actual level of Pg deficiency in the United States in Canada. It seems to me the figure should exceed 500.
Interestingly, Martin has totally ignored the acquired deficiency apps of Pg such as treating patients with severe burns and acute lung injury. The latter could be a rather large market probably several hundreds of $M/yr. These acute deficiency apps are considered low hanging fruit and you have to wonder why Martin has chosen to ignore them.
Instead he has focussed on diabetic ulcers he completely ignored all the work that Omnio has done in this area and others. Diabetic ulcers represents a potentially huge market for Pg as we all know. Quite amazing that Martin is so dismissive.
On the upcoming IPF trials, Martin is cautious. for a variety of reasons which I am not in a position to judge. What will be telling is whether PLI is able to partner up with Big Pharma to take the IPF trials forward. If PLI is successful here then Martin's notes of caution can be thrown into the garbage bin.